1 / 66

Vaccine Economics: Diseases, Dollars, and Dilemmas

Vaccine Economics: Diseases, Dollars, and Dilemmas. Tracy Lieu, MD, MPH. Center for Child Health Care Studies, Depts of Ambulatory Care and Prevention and Pediatrics, Harvard Medical School and Harvard Pilgrim Health Care. Topics. Economic factors pose barriers to optimal vaccine use

devin
Download Presentation

Vaccine Economics: Diseases, Dollars, and Dilemmas

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Vaccine Economics:Diseases, Dollars, and Dilemmas Tracy Lieu, MD, MPH Center for Child Health Care Studies, Depts of Ambulatory Care and Prevention and Pediatrics, Harvard Medical School and Harvard Pilgrim Health Care

  2. Topics • Economic factors pose barriers to optimal vaccine use • Placing the right value on vaccines • Making the right recommendations for vaccines in the U.S. • Getting the right vaccines made for developing countries

  3. Topics • Economic factors pose barriers to optimal vaccine use • Placing the right value on vaccines • Making the right recommendations for vaccines in the U.S. • Getting the right vaccines made for developing countries

  4. Source: USA Today, Thursday, October 28, 2004; 1A

  5. Prices of Old and New Vaccines

  6. Contrasts Between Old and New Vaccines Old • Biologically simpler • Two or more manufacturers • Lower cost • New • Biologically complex • Single manufacturer • Higher cost

  7. Benefit-to-cost ratiosfor childhood vaccines, US health care system DTP 6:1 MMR 16:1 Polio 3:1 Hib 3:1

  8. Cost of immunizing a US child CDC/NIP

  9. Projected deaths prevented by vaccination of US children

  10. Topics • Economic factors pose barriers to optimal vaccine use • Placing the right value on vaccines • Making the right recommendations for vaccines in the U.S. • Getting the right vaccines made for developing countries

  11. Cost-Effective = Cost-Saving Health Outcomes or = Costs

  12. Different Perspectives, Different Costs

  13. Pneumococcal Conjugate Vaccine Background • Leading bacterial cause of meningitis, pneumonia, otitis media • New vaccine found effective in randomized trial in 1999 • Vaccine price announced at $58 per dose

  14. Cost of immunizing a US child CDC/NIP

  15. Projected Benefits and Costs of Routine Pneumococcal Vaccination of U.S. Children Decision analysis • Decision tree • Probabilities • Costs • Base case analysis • Sensitivity analyses Lieu JAMA 2000;283:1460-68

  16. Death Disability Meningitis Deafness No sequelae Bacteremia Pneumonia Complex otitis media Simple otitis media Pneumococcal infection

  17. Projected Benefits Lieu JAMA 2000;283:1460-68

  18. Medical Savings

  19. Cost-Effectiveness • Net cost = $172 million • Cost-effectiveness ratio = $80,000 per life-year saved • Problem: Doesn’t give credit for preventing meningitis, bacteremia, pneumonia, or otitis media Lieu JAMA 2000;283:1460-68

  20. Quality-adjusted life-years (QALYs) • Simplified definition: 1 QALY = 1 year in perfect health • QALYs are a standardized measure to: • Give credit for preventing disease • Weigh benefit of preventing disease against the harm of vaccine reactions • Make comparisons with other vaccines and health services

  21. Time-Tradeoff Questionto Measure QALYs Example: Meningitis • Imagine that you have a 1-year-old child • Very fussy with high fever for 1-2 days • Pediatrician does tests, including spinal tap • Hospitalized for IV antibiotics for 10 days • No additional problems • How much of your life, if any, would you trade to prevent this? Prosser Pediatrics 2004;113:283-90

  22. Time-Tradeoff Resultsfrom Community Respondents Prosser Pediatrics 2004;113:283-90

  23. How QALYs Change the Appraisal of Cost-Effectiveness Prosser Pediatrics 2004;113:283-90; Lieu Health Affairs in press

  24. Comparisons with Other Preventive Health Services

  25. Impact • Policy • Pneumococcal vaccination recommended for U.S. infants in 2000 • Scientific • Need to measure nonmonetary benefits to place appropriate value on vaccines

  26. Institute of Medicine 2004Financing Vaccines in the 21st Century “ACIP (or some other advisory body) should conduct an analysis to determine the monetary value to society of each vaccine.” “The calculation of nonmonetary benefits can draw on a substantial literature that suggests monetary values for years of life gained. Quality-of life and disability measurements are also standard in the literature.”

  27. Issues to Discuss • Whose values to use? • Community members, patients or parents, providers • How to value short-term, vs. chronic, health states? • How to address skepticism about economic approaches to measuring health benefit (utility assessment, contingent valuation)?

  28. Topics • Economic factors pose barriers to optimal vaccine use • Placing the right value on vaccines • Making the right recommendations for vaccines in the U.S. • Getting the right vaccines made for developing countries

  29. 300,000 250,000 200,000 Number of cases 150,000 100,000 50,000 0 1922 1930 1940 1950 1960 1970 1980 1990 2000 Year Reported Pertussis Cases U.S., 1922-2004* DTwP * 2004 provisional

  30. 20,000 18,000 16,000 14,000 12,000 10,000 8,000 6,000 4,000 2,000 0 1980 1990 2000 Number of cases All ages <7 yrs Year

  31. Pertussis -- Background • Increases in infant pertussis, with 16 deaths in 2004 • Suggests pertussis circulation is increasing due to waning immunity • Acellular pertussis vaccines for adolescents and adults developed

  32. Pertussis Policy Decision Pertussis No vaccination No pertussis Adolescents one dose Adolescents + adults every 10y Adults one dose Adults every 10y Parents of infants (Cocoon) Public health policy

  33. Incidence, Cost, and QALYs • Empirical studies via Massachusetts enhanced pertussis surveillance system • Retrospective analysis of 2600 cases for medical costs • Prospective telephone interviews of 500 cases for time costs and QALYs Lee Clin Infect Dis 2004;39:1572-80

  34. Pertussis Incidence and Cost Lee Clin Infect Dis 2004;39:1572-80

  35. Medical Costs of Adolescent Pertussis

  36. Pertussis Vaccine

  37. Measuring QALYs:Time-Tradeoff Method Example: Severe cough How many days or weeks would you be willing to give up from the end of your life to avoid severe cough for 8 weeks? The cough can cause vomiting several times a week, difficulty eating or drinking, and difficulty sleeping. Lee Health Qual Life Outcomes 2005;3:17

  38. Time-Tradeoff Results Lee Health Qual Life Outcomes 2005;3:17

  39. Cost-Effectiveness in US 2004 dollars, at vaccine price = $15 Lee Pediatrics in press

  40. Comparisons with Other Vaccines • From the societal perspective: • $ per $ per • case QALY or life-yr prevented saved • Varicella 1 dose Saving Saving • Hepatitis B Saving Saving • Pneumococcal 200* 4,700 per QALY • Pertussis 1,100 19,000 per QALY • Meningococcal 600,000 120,000 per life-yr * Includes otitis media, pneumonia, meningitis, and bacteremia.

  41. Comparisons with Other Preventive Health Services

  42. Impact • Policy – ACIP this June • Decision on adolescent vaccination? • Discussion of adult vaccination • Scientific • Disease burden, cost, and cost-effectiveness are only a few of the key factors

  43. Upcoming DecisionsAdvisory Committee on Immunization Practices

  44. Policy-Related Factors Feudtner & Marcuse Pediatrics 2001;107:1158-64

  45. Issues to Discuss • How should we incorporate these policy-related factors in vaccine decisions? • Explicit measurement • Explicit process • Should ACIP continue to issue “one size fits all” recommendations? • Current approach leads to gaps in financing • How should clinicians deal with “optional” vaccines?

More Related